Abstract

Background: Breast cancer (BC) is the most common malignancy in women and the second greatest cause of cancer death. There are relatively little data available on the role of autophagy markers in pathogenicity of breast cancer in the Iraqi population. We have therefore investigated the role of Baclin-1 and LC3-B in pathogenicity of breast cancer in Iraqi women. Methods: A case-control study was conducted to assess the role of Bacline-1 and LC3-B in pathogenicity of breast cancer in Iraqi women. The study included 50 patients with BC age matched with 50 healthy individuals served as a control group. The Baclin-1 and LC3-B concentrations were determined by enzyme-linked immunosorbent assay (ELISA) technique. Results: Body mass index (BMI) were significantly increase in patients with BC compared to the controls. Serum Baclin-1 and LC3-B levels in cases were significantly higher (P= 0.001) than those in controls. According to histological tumor characteristics. Grade 2 and stage IIA were significantly higher in BC patients and the tumor grade and stage did not show any significant associations with serum levels of Bacline-1 and LC3-B. No significant correlation between serum levels of Baclin-1 and LC3-B (r = 0.034; P = 0.812). Conclusion: The study indicated that the Beclin-1 and LC3-B my consider a good biomarkers for progression of BC and it could be a therapeutic target to reduce the aggressiveness of disease. Keywords: Breast cancer; Baclin-1; Light Chain3B.

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.